FurlongMLeggattM.Reconciling the patient's right to confidentiality and the family's need to know. Australian and New Zealand Journal of Psychiatry1996; 30:614–622.
2.
CramptonELGlassRCMarchantBReissJA.Chemical ionisation mass fragmentographic measurement of dothiepin plasma concentrations following a single oral dose in man. Journal of Chromatography1980; 183:141–148.
3.
BertilssonLAberg-WistedTAGustafssonLLNordinC.Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Therapeutic Drug Monitoring1985; 7:478–480.
4.
MahgoubAIdleJRDringLGLancasterRSmithRL.Polymorphic hydroxylation of debrisoquine in man. Lancet1977; 2:584–586.
5.
HeimMMyereUA.Genotyping of poor metabolisers of debrisoquine by allele-specific amplification. Lancet1990; 336:529–532.
6.
MyerUAAmreinRBalantLPAntidepressants and drug-metabolising enzymes—expert group report. Acta Psychiatrica Scandinavica1996; 93:71–79.
7.
PattonG.An epidemiological case for a separate adolescent psychiatry. Australian and New Zealand Journal of Psychiatry1996; 30:563–566.
8.
HallGS.Adolescence: its psychology and its relations to physiology, anthropology, sociology, sex, crime, religion and education. London: Sidney Appleton, 1905.
9.
FeldmanSSElliotGR.At the threshold: the developing adolescent. Cambridge MA: Harvard University Press, 1990.
10.
JonesPRodgersBMurrayRMarmotM.Child developmental risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet1994; 344:1398–1402.
11.
ChattertonRCardySSchrammTM.Neuroleptic malignant syndrome and clozapine monotherapy. Australian and New Zealand Journal of Psychiatry1996; 30:692–693.
12.
PopeHGKeckPEMcElroySL.Frequency and presentation of neuropleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry1986; 143:1227–1233.
13.
LevensonJL.Neuroleptic malignant syndrome. American Journal of Psychiatry1985; 142:1137–1145.
14.
RosebushPStewartTA.Prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry1989; 146:717–725.
15.
VelamorVRSwamyGNParmarRSWilliamsonPCaroffSN.Management of suspected neuroleptic malignant syndrome. Canadian Journal of Psychiatry1995; 40:545–550.
16.
ReillyJJCroweSFLloydJH.Neuroleptic toxicity syndrome: a clinical spectrum. Australian and New Zealand Journal of Psychiatry1991; 25:499–505.
ModestinJTofflerGDrescherJP.Neuroleptic malignant syndrome: results of a prospective study. Psychiatric Research1992; 44:251–256.
19.
VelamorVRNormanRMGCaroffSNMannSCSullivanKAAnteloRE.Progression of symptoms in neuroleptic malignant syndrome. Journal of Nervous and Mental Diseases1994; 182:168–173.
20.
GoatsMGEscobarJLAn apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of a clozapine therapy: report of a case and results of a clozapine rechallenge. Journal of Clinical Psychopharmacology1992; 12:139–140.
21.
AdityanjeeSingh SSinghGOngS.Spectrum concept of neuroleptic malignant syndrome. British Journal of Psychiatry1988; 153:107–111.
22.
NopoulosPFlaumMMillerDD.Atypical neuroleptic malignant syndrome (NMS) with an atypical neuroleptic: clozapine-induced NMS without rigidity. Annals of Clinical Psychiatry1990; 2:251–253.
23.
SachdevPKrukJKneeboneMKissaneD.Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. Journal of Clinical Psychopharmacology1995; 5:365–371.
24.
BeautraisALJoycePRMulderRT.Access to firearms and the risk of suicide: a case control study. Australian and New Zealand Journal of Psychiatry1996; 30:741–748.
25.
BruzziPGreenSBByarDPBrintonLASchairerC.Estimating the population attributable risk for multiple risk factors using case-control data. American Journal of Epidemiology1985; 122:904–914.
